mFOLFOX7方案治疗晚期胃癌78例临床观察

Observation of mFOLFOX7 regimen in treatment of 78 patients with advanced gastric cancer

目的:观察mFOLFOX7方案治疗晚期胃癌的疗效和毒副反应。方法:采用mFOLFOX7方案:奥沙利铂130mg/m2静脉滴入2h,d1;亚叶酸钙200mg/m2静脉滴入1～1.5h,d1;再予5-FU2400mg/m2持续泵控静脉推注(5mL/h)46h,每3周为1个周期。所有患者至少接受2个周期化疗,2个周期后采用WHO标准评价疗效。结果:78例患者中完全缓解(CR)3例,部分缓解(PR)42例,稳定(SD)17例,进展(PD)16例,总有效率57.7%,中位进展7个月,中位生存期为9个月,临床受益(CR+PR+SD)62例(79.5%)。骨髓抑制、胃肠道反应及神经毒性是主要的不良反应,这些不良反应均可逆,无治疗相关死亡。结论:mFOLFOX7方案治疗晚期胃癌有效率及临床受益率较高,是晚期胃癌化疗较为理想的方案。

OBJECTIVE：To observe the efficacy and toxicity of mFOLFOX7 regimen for patients with advanced gastric cancer.METHODS：The regimen was oxaliplatin 130 mg/m2,ivdrip 2 h,d1,calcium folinate 200 mg/m2 ivdrip,1-1.5 h,d1,followed by 5-FU 2 400 mg/m2,iv 46 h（5 mL/h）.The chemotherapy was repeated every 3 weeks for one cycle.All the patients received two cycles of chemotherapy at least.The efficacy and toxicity were evaluated according to the WHO standard.RESULTS：There were 3 patients showing a complete response,42 partial response,17 steady diseaset,and 16 progressive disease.The total response rate was 57.6%.The median time to progression（mTTP）was 7 months,and the median overall survival（mOS）was 9 months for all the patients,and the clinical benefit response（CR＋PR＋SD）was in 62 cases（79.5%）.The toxicity could be assessed in all the patients and the principal adverse events were neural toxicity,gastrointestinal effect and myolesuppression and they were reversed.There was no death during the treatment.CONCLUSION：mFOLFOX7 is an effective and well tolerated regimen in the treatment of advanced gastric cancer.